Renewal of the Hematology-Oncology Associates of Central New York (HOACNY) CCOP grant will enable us to continue to participate in NCI sponsored treatment and cancer control studies. We are currently following hundreds of patients on treatment trials and cancer control and prevention trials. Continuation of the grant will not only enable us to continue to follow these patients but to accrue additional individuals to such studies. Our clinical research department continues to work closely with the entire staff of HOACNY to identify eligible patients for treatment and symptom control studies. We actively recruit high-risk individuals from a large area of Central New York for cancer prevention studies. We have greatly expanded the participants in our CCOP (14 full time medical and radiation oncologists with 3 more to join soon), which will better serve our geographical region. The availability of a wide range of treatment and cancer control protocols improves the overall care of cancer patients in our community. The entire CCOP staff continues to not only provide """"""""state of the art"""""""" care to our patients but also serves as a valuable resource to local health care providers and educates the entire CNY community in terms of cancer treatment and prevention. Our goal is to maintain the CCOP at a high level in terms of quantity and quality and to further increase our efforts in terms of cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045389-27
Application #
8479126
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Good, Marge
Project Start
1987-07-21
Project End
2014-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
27
Fiscal Year
2013
Total Cost
$518,435
Indirect Cost
$295,138
Name
Hematology-Oncology Associates/Ctl NY
Department
Type
DUNS #
101317097
City
East Syracuse
State
NY
Country
United States
Zip Code
13057
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Burstein, Harold J; Cirrincione, Constance T; Barry, William T et al. (2014) Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women J Clin Oncol 32:3959-66
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20
Grant, Barbara W; Jung, Sin-Ho; Johnson, Jeffrey L et al. (2013) A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119:3797-804
Ogino, Shuji; Shima, Kaori; Meyerhardt, Jeffrey A et al. (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900

Showing the most recent 10 out of 63 publications